Title : Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.

Pub. Date : 2015 Mar

PMID : 25480878






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Among women treated with anthracycline with or without taxane regimens, the pCR rate was 57.1% for BRCA1 carriers, 29.0% for non-carriers (P < 0.001); among women treated with taxane regimens, the pCR rate was 40.0% for BRCA1 carriers, 32.9% for non-carriers (P = 0.73). Anthracyclines BRCA1 DNA repair associated Homo sapiens
2 Among women treated with anthracycline with or without taxane regimens, the pCR rate was 57.1% for BRCA1 carriers, 29.0% for non-carriers (P < 0.001); among women treated with taxane regimens, the pCR rate was 40.0% for BRCA1 carriers, 32.9% for non-carriers (P = 0.73). Anthracyclines BRCA1 DNA repair associated Homo sapiens
3 Among triple-negative breast cancer patients, BRCA1 carriers are more likely to respond to neoadjuvant anthracycline-based regimens than are non-carriers. Anthracyclines BRCA1 DNA repair associated Homo sapiens